Posted by Michael Wonder on 19 Jun 2025
Final draft guidance finds benefits of two treatments for patients with Alzheimer’s disease remain too small to justify the additional cost to the NHS
19 June 2025 - The benefits from donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
The committee’s conclusion in final draft guidance published today remains that neither medicine can be recommended for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease.
